Kaleido Biosciences Inc
OTC:KLDO
Kaleido Biosciences Inc
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The company is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development as prevention of infections caused by multi-drug resistant (MDR) bacteria. Nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers, as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The company is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development as prevention of infections caused by multi-drug resistant (MDR) bacteria. Nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers, as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
